Performance of Medtronic Hybrid Closed-Loop Iterations, Results from a Randomized Trial in Adolescents with Type 1 Diabetes

Martin de Bock; Julie Dart; Michael Hancock; Grant Smith; Elizabeth A. Davis; Timothy W. Jones

doi:10.1089/dia.2018.0161

Performance of Medtronic Hybrid Closed-Loop Iterations, Results from a Randomized Trial in Adolescents with Type 1 Diabetes

Martin de Bock, Julie Dart, Michael Hancock, Grant Smith, Elizabeth A. Davis, Timothy W. Jones

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA(1c)) 7.0%-10%, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements. Participants attended a 7-day and 7-night nonstructured camp setting. Twelve participants (mean age 15 years, seven males, five females, mean HbA(1c) 8.55%) completed the study. For the control group, time in target glucose sensor range (3.9-10mmol/L) was 63.68%+/- 10.74% at baseline and changed to 75.85%+/- 8.49% during the study (relative 19%). Time spent in

Original language	English
Pages (from-to)	693-697
Number of pages	5
Journal	Diabetes Technology & Therapeutics
Volume	20
Issue number	10
DOIs	https://doi.org/10.1089/dia.2018.0161
Publication status	Published - Oct 2018

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/dia.2018.0161

Cite this

@article{6f60210992834abe8959596486b801bd,

title = "Performance of Medtronic Hybrid Closed-Loop Iterations, Results from a Randomized Trial in Adolescents with Type 1 Diabetes",

abstract = "This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA(1c)) 7.0%-10%, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements. Participants attended a 7-day and 7-night nonstructured camp setting. Twelve participants (mean age 15 years, seven males, five females, mean HbA(1c) 8.55%) completed the study. For the control group, time in target glucose sensor range (3.9-10mmol/L) was 63.68%+/- 10.74% at baseline and changed to 75.85%+/- 8.49% during the study (relative 19%). Time spent in",

keywords = "Type 1 diabetes, Closed loop, Pediatrics",

author = "{de Bock}, Martin and Julie Dart and Michael Hancock and Grant Smith and Davis, {Elizabeth A.} and Jones, {Timothy W.}",

year = "2018",

month = oct,

doi = "10.1089/dia.2018.0161",

language = "English",

volume = "20",

pages = "693--697",

journal = "Diabetes Technology & Therapeutics",

issn = "1557-8593",

publisher = "Mary Ann Liebert Inc",

number = "10",

}

TY - JOUR

T1 - Performance of Medtronic Hybrid Closed-Loop Iterations, Results from a Randomized Trial in Adolescents with Type 1 Diabetes

AU - de Bock, Martin

AU - Dart, Julie

AU - Hancock, Michael

AU - Smith, Grant

AU - Davis, Elizabeth A.

AU - Jones, Timothy W.

PY - 2018/10

Y1 - 2018/10

N2 - This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA(1c)) 7.0%-10%, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements. Participants attended a 7-day and 7-night nonstructured camp setting. Twelve participants (mean age 15 years, seven males, five females, mean HbA(1c) 8.55%) completed the study. For the control group, time in target glucose sensor range (3.9-10mmol/L) was 63.68%+/- 10.74% at baseline and changed to 75.85%+/- 8.49% during the study (relative 19%). Time spent in

AB - This study investigates the performance of an iteration of the Medtronic hybrid closed-loop (HCL) algorithm, which utilizes sensor glucose values non-adjunctively for bolus advice, recognizes sustained hyperglycemia, suggests insulin bolus correction, and includes more accommodative SmartGuard automode parameters that aim to improve function and usability. Adolescents aged 13-17 years with type 1 diabetes >1 year, glycated hemoglobin (HbA(1c)) 7.0%-10%, currently using Continuous Subcutaneous Insulin Infusion were randomized to the control Medtronic standard HCL algorithm or to the intervention Medtronic HCL with enhancements. Participants attended a 7-day and 7-night nonstructured camp setting. Twelve participants (mean age 15 years, seven males, five females, mean HbA(1c) 8.55%) completed the study. For the control group, time in target glucose sensor range (3.9-10mmol/L) was 63.68%+/- 10.74% at baseline and changed to 75.85%+/- 8.49% during the study (relative 19%). Time spent in

KW - Type 1 diabetes

KW - Closed loop

KW - Pediatrics

U2 - 10.1089/dia.2018.0161

DO - 10.1089/dia.2018.0161

M3 - Article

C2 - 30204486

VL - 20

SP - 693

EP - 697

JO - Diabetes Technology & Therapeutics

JF - Diabetes Technology & Therapeutics

SN - 1557-8593

IS - 10

ER -

Performance of Medtronic Hybrid Closed-Loop Iterations, Results from a Randomized Trial in Adolescents with Type 1 Diabetes

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this